Skip to main content
Top
Published in: Endocrine 2/2020

01-08-2020 | Cushing's Syndrome | Endocrine imaging

Periprostatic paraganglioma causing occult Cushing’s syndrome

Authors: Mojca Jensterle, Luka Lezaic, Jera Jeruc, Andrej Janez

Published in: Endocrine | Issue 2/2020

Login to get access

Excerpt

A 25-year-old Caucasian male noticed the onset of poor concentration, depression, occasional paranoid feelings, loss of libido and insomnia. Over a 12-month period he gradually developed a Cushingoid appearance. At first examination he had low serum potassium 2.7 mmol/l (reference range, 3.8–5.5), an elevated midnight cortisol 2202 nmol/l (reference range, <50) and ACTH 34 pmol/l (reference range <10.2). High-dose dexamethasone suppression test and bilateral inferior petrosal sinus sampling with CRH stimulation were consistent with an ectopic Cushing syndrome (ECS) [1]. He started with metyrapone therapy. Ketoconazole was added several months later. Mean cortisol was maintained between 200 and 350 nmol/l, while ACTH level had increased on these medications, varying between 173 and 479 ng/l. …
Literature
Metadata
Title
Periprostatic paraganglioma causing occult Cushing’s syndrome
Authors
Mojca Jensterle
Luka Lezaic
Jera Jeruc
Andrej Janez
Publication date
01-08-2020
Publisher
Springer US
Published in
Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02335-z

Other articles of this Issue 2/2020

Endocrine 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.